DJIA 17,753.58 2.19 0.01%
NASDAQ 5,130.17 18.43 0.36%
S&P 500 2,108.84 0.27 0.01%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplusĀ® platform

FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs

3 Soaring Clinical-Stage Biotechs, and 1 to Buy

One Motley Fool digs into three top performing biotech stocks and discovers one that may still be worth buying.

Short-Sellers Betting Against These Biotechs

What Propelled Sarepta Therapeutics' Stock 19% Higher in June?

Clinical-stage biopharmaceutical company Sarepta Therapeutics roared higher in June. Find out what was behind this big move and whether it has the legs to push higher.

Catabasis Up on Fast Track Status for DMD Drug CAT-1004 - Analyst Blog

Several Biotech Stocks Indicating A Macro Short Strategy

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Pre

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases

Cramer Is Flying Southwest, Won't Recommend Sarepta Therapeutics

Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Ana

Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
See More Articles...